1-methyl-4-phenyl-2,3-dihydropyridinium has been researched along with 1-methyl-4-phenylpyridinium in 19 studies
| Studies (1-methyl-4-phenyl-2,3-dihydropyridinium) | Trials (1-methyl-4-phenyl-2,3-dihydropyridinium) | Recent Studies (post-2010) (1-methyl-4-phenyl-2,3-dihydropyridinium) | Studies (1-methyl-4-phenylpyridinium) | Trials (1-methyl-4-phenylpyridinium) | Recent Studies (post-2010) (1-methyl-4-phenylpyridinium) |
|---|---|---|---|---|---|
| 46 | 0 | 3 | 1,854 | 1 | 593 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 9 (47.37) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Delanney, LE; Di Monte, DA; Irwin, I; Langston, JW; Wu, EY | 1 |
| Das, NP; Moochhala, SM; Sato, T; Shahi, GS; Sunamoto, J | 1 |
| Di Monte, DA; Langston, JW; Wu, EY | 1 |
| Jenner, P; Marsden, CD; Walker, MJ | 1 |
| Doyle, TJ; Lau, YS; Wilson, JA | 1 |
| Brossi, A; Chiueh, CC; Gessner, W; Johannessen, JN; Namura, I; Singhaniyom, W; Sun, CJ | 1 |
| Castagnoli, N; Ramsay, RR; Singer, TP; Trevor, AJ | 1 |
| Di Monte, D; Ekström, G; Sandy, MS; Smith, MT | 1 |
| Jonsson, G; Luthman, J; Nwanze, E; Sundström, E | 1 |
| Crabtree, D; Salach, JI; Singer, TP | 1 |
| Adams, JD; Klaidman, LK; Leung, AC | 1 |
| McCrodden, JM; Sullivan, JP; Tipton, KF | 1 |
| Cosi, C; Marien, M | 1 |
| Niki, E; Noguchi, N; Shi, H; Xu, Y | 1 |
| Coates, PW; Everse, J | 1 |
| Galisteo, J; Guillén, H; Herraiz, T | 1 |
| Gwizdek-Wiśniewska, A; Piosik, J; Ulanowska, K; Wegrzyn, G | 1 |
| Herraiz, T | 1 |
| Brunner, T; Cirri, E; Ferger, B; Friemel, A; Hiller, K; Karreman, C; Leist, M; Marx, A; Meiser, J; Möller, HM; Odermatt, M; Pape, R; Pasquarelli, N; Ringwald, M; Schildknecht, S; Strittmatter, T | 1 |
1 review(s) available for 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium
| Article | Year |
|---|---|
Metabolic aspects of the behavior of MPTP and some analogues.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; Humans; Monoamine Oxidase; Parkinson Disease, Secondary; Pyridinium Compounds; Structure-Activity Relationship; Substantia Nigra | 1993 |
18 other study(ies) available for 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium
| Article | Year |
|---|---|
Production and disposition of 1-methyl-4-phenylpyridinium in primary cultures of mouse astrocytes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Astrocytes; Biotransformation; Bucladesine; Cell Death; Cells, Cultured; Extracellular Space; Mice; Monoamine Oxidase; Prosencephalon; Pyridinium Compounds | 1992 |
Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its toxic metabolites on the physicochemical property of the liposomal membrane in relation to their cytochrome P-450 inhibition.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cytochrome P-450 CYP1A1; Cytochrome P-450 Enzyme Inhibitors; Dimyristoylphosphatidylcholine; Fluoresceins; Fluorescent Dyes; Kinetics; Liposomes; Male; Membrane Fluidity; Mice; Mice, Inbred C57BL; Microsomes, Liver; Oxidoreductases; Pyridinium Compounds; Spectrometry, Fluorescence | 1992 |
Toxicity of the 1-methyl-4-phenyl-2,3-dihydropyridinium and 1-methyl-4-phenylpyridinium species in primary cultures of mouse astrocytes.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Animals; Astrocytes; Cells, Cultured; Glucose; L-Lactate Dehydrogenase; Mice; Pyridinium Compounds | 1992 |
A redox reaction between MPP+ and MPDP+ to produce superoxide radicals does not impair mitochondrial function.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Free Radicals; Male; Mitochondria; MPTP Poisoning; Oxidation-Reduction; Oxygen Consumption; Pyridinium Compounds; Rats; Rats, Inbred Strains; Spectrophotometry, Ultraviolet; Superoxide Dismutase; Superoxides | 1991 |
MPTP, MPDP+ and MPP+ cause decreases in dopamine content in mouse brain slices.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dopamine; In Vitro Techniques; Mice; Mice, Inbred C57BL; Pyridinium Compounds | 1990 |
Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.
Topics: 1-Methyl-4-phenylpyridinium; Amphetamines; Animals; Apomorphine; Corpus Striatum; Dopamine; Male; Piperazines; Pyridinium Compounds; Rats; Rats, Inbred Strains; Stereotyped Behavior; Substantia Nigra | 1988 |
Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Biotransformation; Brain; Humans; Mitochondria; Monoamine Oxidase; NAD; Parkinson Disease, Secondary; Pyridines; Pyridinium Compounds; Rats | 1987 |
Comparative toxicity and antioxidant activity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and its monoamine oxidase B-generated metabolites in isolated hepatocytes and liver microsomes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; In Vitro Techniques; Lipid Peroxides; Liver; Male; Microsomes, Liver; Monoamine Oxidase; Pyridines; Pyridinium Compounds; Rats; Rats, Inbred Strains | 1987 |
Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Brain; Dopamine; Fluorescent Antibody Technique; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Monoamine Oxidase; Neurons; Norepinephrine; Pyridines; Pyridinium Compounds | 1986 |
Reversible inhibition and mechanism-based irreversible inactivation of monoamine oxidases by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Brain; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridines; Pyridinium Compounds; Spectrophotometry | 1985 |
MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cattle; Cyclic N-Oxides; Ethanol; Free Radicals; Hydrogen Peroxide; Hydroxides; Hydroxyl Radical; Mitochondria, Heart; NADH Dehydrogenase; Pyridinium Compounds; Reactive Oxygen Species; Spin Labels; Submitochondrial Particles | 1993 |
Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Benzamides; Brain Chemistry; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dopamine Agents; Frontal Lobe; Male; Mesencephalon; Mice; Mice, Inbred C57BL; NAD; Neuroprotective Agents; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proteins; Pyridinium Compounds | 1998 |
1-Methyl-4-phenyl-2,3-dihydropyridinium is transformed by ubiquinone to the selective nigrostriatal toxin 1-methyl-4-phenylpyridinium.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Biotransformation; Liposomes; Male; Monoamine Oxidase; Neurotoxins; Oxidation-Reduction; Pyridinium Compounds; Rats; Rats, Wistar; Synaptosomes; Ubiquinone | 1999 |
The cytotoxic activity of lactoperoxidase: enhancement and inhibition by neuroactive compounds.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apomorphine; Aspirin; Brain; Catalysis; Cell Line, Tumor; Dogs; Dopamine; Erythrocytes; Free Radicals; Herbicides; Humans; Lactoperoxidase; Neurons; Parkinson Disease; Peroxidase; Pyridinium Compounds; Spectrophotometry; Time Factors; Uric Acid | 2004 |
N-methyltetrahydro-beta-carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic beta-carbolinium cations by heme peroxidases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Cations; Chromatography, High Pressure Liquid; Heme; Kinetics; Models, Chemical; Neurotoxins; Oxidation-Reduction; Peroxidases; Pyridinium Compounds; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet | 2007 |
Impaired mutagenic activities of MPDP(+) (1-methyl-4-phenyl-2,3-dihydropyridinium) and MPP(+) (1-methyl-4-phenylpyridinium) due to their interactions with methylxanthines.
Topics: 1-Methyl-4-phenylpyridinium; Caffeine; Calorimetry; Drug Interactions; Models, Molecular; Molecular Structure; Mutagens; Pentoxifylline; Pyridinium Compounds; Spectrophotometry, Atomic; Vibrio | 2007 |
Evaluation of the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to toxic pyridinium cations by monoamine oxidase (MAO) enzymes and its use to search for new MAO inhibitors and protective agents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Carbolines; Chromatography, High Pressure Liquid; Clorgyline; Enzyme Assays; Harmine; Humans; Indazoles; Isoenzymes; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Nicotiana; Oxidation-Reduction; Pyridinium Compounds; Recombinant Proteins; Selegiline; Smoke; Vitamin K 3 | 2012 |
Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP+ by Transporter-Independent Export of the Intermediate MPDP+.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Astrocytes; Biological Transport; Catecholamines; Cell Line; Cell Membrane; Diffusion; Dopaminergic Neurons; Extracellular Fluid; Humans; Monoamine Oxidase; Oxidation-Reduction; Parkinson Disease; Pyridinium Compounds | 2015 |